Publikation
High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Wissenschaftlicher Artikel/Review - 01.06.2023
Zhou Xiang, Besse Andrej, Peter Jessica, Steinhardt Maximilian Johannes, Vogt Cornelia, Nerreter Silvia, Teufel Eva, Stanojkovska Emilia, Xiao Xianghui, Hornburger Hannah, Haertle Larissa, Mendez Lopez Max, Munawar Umair, Riedel Angela, Han Seungbin, Maurits Elmer, Overkleeft Hermann S, Florea Bogdan I, Einsele Hermann, Kortüm K Martin, Driessen Christoph, Besse Lenka, Rasche Leo